Fazal Khan

Dr. Fazal Khan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
SDSina Danesh
Sina Danesh
FKFazal Khan
Fazal Khan
TCTrevor Chopko
Trevor Chopko
ALAurora Lee
Aurora Lee
RHRan Huo
Ran Huo
PTPaul C. Tang
Paul C. Tang
Background: Postoperative atrial fibrillation occurs in ~40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden. We evaluated the association of preoperative MRA use with postoperative atrial fibrillation and investigated atrial cell types modulated by MRAs during cold preservation. Methods: We studied 19 042 cardiac surgery patients at Mayo Clinic. Propensity 1:3 matching identified 298 MRA users and 894 non‐users. A subgroup analysis of patients on any preoperative diuretic was performed to isolate cardiac‐specific effects of MRAs, matching 298 MRA users to 894 non‐MRA diuretic users. AF recurrence was assessed for up to 6‐years. Single‐nucleus RNA sequencing (snRNA‐seq) was performed on human donor atria exposed to canrenone (a water‐soluble MRA) during cold preservation with ex‐vivo reperfusion, and expression profiles were compared with atria from patients with AF. Results: After matching, preoperative MRA use was associated with a lower incidence of postoperative atrial fibrillation (19.8% versus 31.8%, P <0.001). In the diuretic‐only subgroup, MRA users also had lower postoperative atrial fibrillation (19.8% versus 33.2%, P <0.001). MRA use was associated with a reduced incidence of paroxysmal and chronic AF at 6‐years. snRNA‐seq identified a cardiomyocyte subpopulation, CM2, with high mineralocorticoid receptor expression where canrenone suppressed cold preservation‐induced mineralocorticoid receptor target gene expression, which was conversely elevated in chronic AF. Canrenone also attenuated stress‐response in atrial macrophages and pericytes. Conclusions: Preoperative MRAs were associated with reduced postoperative and long‐term AF after cardiac surgery. Mechanistically, our ex‐vivo human atrial model revealed that MRAs suppress mineralocorticoid receptor ‐driven atrial stress responses, particularly in conduction‐relevant cardiomyocytes.

23 July 2024 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
FKFazal Khan
Fazal Khan
TCTrevor C Chopko
Trevor C Chopko
SMSimon Maltais
Simon Maltais
JSJohn Stulak
John Stulak
Cardiac fistulas present diagnostical and therapeutical challenges due to their variability in size, shape and pathway. Three-dimensional printing is increasingly used to provide a tactile representation that aids in preoperative planning and patient education. We present the case of a female in her 60s who developed a fistula between the left ventricle, right atrium and coronary sinus 2 years after bioprosthetic valve replacement. We used three-dimensional modelling to better understand her cardiac anatomy and optimise our surgical approach. She was discharged home without deficit following an uneventful postoperative course. Three-dimensional printing can improve patient care through tangible demonstration, preoperative planning and trainee education.

28 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SDSina Danesh
Sina Danesh
FKFazal Khan
Fazal Khan
TCTrevor Chopko
Trevor Chopko
ALAurora Lee
Aurora Lee
RHRan Huo
Ran Huo
PTPaul C. Tang
Paul C. Tang
Background: New postoperative atrial fibrillation (POAF) occurs in about 40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden. We examined the impact of preoperative MRA use on POAF and also examine the atrial cell type impacted by MRA treatment during cold cardiac preservation. Methods: Retrospective study of 19,042 patients who underwent cardiac surgery at Mayo Clinic in Minnesota, and performed 1:3 propensity matching to obtain 298 patients on preoperative MRA matched to 894 who were not. We also separately matched patients using preoperative diuretics. Single-nuclei RNA sequencing (snRNA-seq) examined MRA’s effects on different atrial cell types in canrenone (water soluble MRA) treated human donor hearts undergoing cold preservation followed by ex-vivo reperfusion and compared gene expression to the atria of patients with AF. Results: Propensity matched preoperative MRA group had less new onset POAF (19.8% vs 31.5%, P<0.001). To account for the possibility that preoperative diuretic use and volume reduction may impact POAF, we propensity matched 298 preop diuretic users that included MRA use to another 894 patients who used a non-MRA diuretic preoperatively. Those who used preoperative MRA similarly had a lower incidence of POAF (19.8% vs 33.2%, P<0.001). No survival difference was present between the propensity matched groups that used preoperative diuretics (P=0.079). Preoperative MRA use also reduced the development of paroxysmal and chronic AF at 6 years of follow up. From our snRNA-seq data, we identified a subpopulation of atrial cardiomyocytes (CM2) that had high MR expression where canrenone suppressed the increase in MR target gene expression associated with cold preservation-reperfusion. These MR targets were conversely elevated in patients with chronic AF. Canrenone also suppressed other cardiac preservation associated genes that show elevated expression in atrial macrophages and pericytes from chronic AF atria. Conclusions: Our studies show that preoperative MRA use is associated with 40% reduction in POAF as well as lowering long standing AF development by about 41%. Our cold cadiac preservation-reperfusion model showed that canrenone reduced expression of MR target genes associated with chronic AF, particular in cardiomyocytes with important roles in electrical conduction. Clinical Perspective: What is New?: This study shows that preoperative use of mineralocorticoid receptors antagonists (MRA) is associated with a reduced incidence of new onset perioperative atrial fibrillation after cardiac surgery utilizing cardiopulmonary bypass. We show that preoperative MRA use is associated with a lower incidence of developing more chronic paroxymal or sustained atrial fibrillation. Addition of canrenone, a clinically utilized water soluble MRA, to cardioplegia solution used during cardiac preservation can attenuate atrial inflammatory reponses and reduce signaling through molecular pathways that promote atrial fibrillation. What are the clinical implications?: Perioperative use of MRAs may be considered to reduce early postoperative atrial fibrillation as well as lowering the risk of developing more chronic atrial arrhythmias. These findings support pursuing a clinical trial to determine the impact of MRA use on atrial arrhythmias following cardiac surgery in the setting of cardiopulmonary bypass with cold cardiac preservation.

13 June 2024 in JTCVS Techniques
Verified
Journal Article
Open access
TCTrevor C. Chopko
Trevor C. Chopko
FKFazal Khan
Fazal Khan
APAlberto Pochettino
Alberto Pochettino

1 January 2019 in Heart Views
Verified
Journal Article
Open access
PDF file
FKFazal Khan
Fazal Khan
SSSameh M Said
Sameh M Said
Aortic root enlargement (ARE) is an established procedure to deal with small aortic annulus. It becomes very important to place adequate size prosthesis to prevent patient–prosthesis mismatch (PPM). Aortic root enlargement procedures procedures are technically demanding operations, particularly in obese patients. The presence of coronary artery anomalies adds more complexity to the procedure. We present an interesting case of a 22-year-old obese female with symptomatic severe aortic valve stenosis and anomalous coronary arteries. We successfully performed aortic valve replacement using the combined Konno aortoventriculoplasty and Manouguian posterior aortic root enlargement. Combined aortic root enlargement techniques techniques should be considered in the presence of major coronary anomalies.

20 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
FKFazal Khan
Fazal Khan
SHStephanie Heller
Stephanie Heller
ELErica Loomis
Erica Loomis
RRRivera Rivera
Rivera Rivera
HSHenry Schiller
Henry Schiller
Introduction: There are many well described approaches to symptomatic hernia management; however, there remains a significant patient population with limited options for a durable ventral hernia repair with reasonable risk of infection and recurrence. Drawing from orthopedic literature, we changed our approach to this clinical problem and developed a palliative ventral herniorrhaphy pathway. Methods: An IRB approved retrospective review (January 2017-June 2019) of patients’ palliative ventral herniorrhaphy was performed. Results: 43 patients included with female preponderance (58.6%) , mean age 61.5 years. The mean BMI was 38.1kg/m2 (IQR: 25.4-62) and 28 patients (65.1%) had a history of prior wound/mesh infection. Repair within 48 hours was performed in 14 patients. Overall polypropylene prosthetic was implanted in 26 patients, and bioprosthetic/absorbable mesh was used in the remaining; , the mean surface area of implanted mesh was 561 cm2. The most common wound complications identified were skin separation (30.2%) and seroma formation (48.8%). Hernia recurrence occurred in 4 (9.3%) patients with mean followup 24.1 months (9-37). Three patients had central lightweight mesh rupture and 1 had recurrence (bioprosthetic mesh); all were subsequently repaired. Conclusion: Despite a small volume of patients, our palliative ventral hernia repair pathway offers durable repair with an acceptable risk of recurrence and mesh infection in patients who would otherwise be considered non-operative. Local surgical site complications were frequent but did not appear to affect the risk of recurrence or long-term complications.